Methods and processes for non-invasive assessment of genetic variations

US9605313B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9605313-B2
Application numberUS-201313782901-A
CountryUS
Kind codeB2
Filing dateMar 1, 2013
Priority dateMar 2, 2012
Publication dateMar 28, 2017
Grant dateMar 28, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for enriching fetal nucleic acid in sample nucleic acid that includes fetal nucleic acid and maternal nucleic acid, comprising: (a) obtaining cell-free circulating sample nucleic acid from a biological sample from a pregnant female; and (b) separating some or substantially all of the fetal nucleic acid from the maternal nucleic acid by contacting the sample nucleic acid with a H1M-specific antibody or H1FOO-specific antibody, thereby generating a separation product enriched for fetal nucleic acid relative to fetal nucleic acid in the sample nucleic acid. 2. The method of claim 1 , wherein the sample nucleic acid is from blood plasma. 3. The method of claim 1 , wherein obtaining the sample nucleic acid comprises subjecting the biological sample to an in vitro process that isolates the sample nucleic acid from other sample components. 4. The method of claim 3 , wherein the in vitro process comprises centrifugation. 5. The method of claim 1 , wherein the separation product comprises about 50% or greater fetal nucleic acid. 6. The method of claim 1 , further comprising sequencing the nucleic acid in the separation product using a nucleotide sequencing process, thereby generating nucleotide sequence reads. 7. The method of claim 6 , further comprising detecting the presence or absence of a genetic variation according to the nucleotide sequence reads wherein the genetic variation is a chromosome aneuploidy. 8. The method of claim 7 , wherein the chromosome aneuploidy is a chromosome 21 aneuploidy.

Assignees

Inventors

Classifications

  • against material from animals or humans · CPC title

  • C12Q1/6883Primary

    for diseases caused by alterations of genetic material · CPC title

  • C12Q1/6804Primary

    Nucleic acid analysis using immunogens (immunoassay G01N33/53) · CPC title

  • Single or double stranded nucleic acid binding proteins · CPC title

  • involving nucleic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9605313B2 cover?
Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations.
Who is the assignee on this patent?
Sequenom Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6883. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).